



Supplementary Figure 1. Synthesis of alkyne macrocyclized peptides. The metathesis reaction was 
optimized using different resins and reaction conditions (Supplementary Table 1). A detailed overview 
of all synthesized peptides (sequences, analytical data) is shown in Supplementary Table 2 and 
Supplementary Table 3. j = number of C-terminal amino acids (2, 6); i = number of amino acids 
between the building blocks (2, 3, 6); k = number of N-terminal amino acids after the last building block 





Supplementary Figure 2. (a) Sequence of the i,i+3 macrocyclized peptide 7 containing N-terminal 
Cys and Met residues. (b) HPLC traces of 7 in the open- (top) and closed conformation (bottom).The 
product peak is highlighted accordingly. (c) Mass spectra of the open- (top) and closed (bottom) 







Supplementary Figure 3. (a) Sequence of the i,i+4 macrocyclized test peptide 8 containing N-
terminal Cys and Met residues. (b) HPLC traces of 8 in the open- (top) and closed conformation 
(bottom).The product peak is highlighted accordingly. (c) Mass spectra of the open- (top) and closed 
(bottom) alkyne crosslink. The HPLC chromatograms are taken from crude reaction mixtures without 





Supplementary Figure 4. (a) Sequence of the i,i+4 macrocyclized test peptide 30 containing N-
terminal Cys and Met residues. The reduced size of the macrocycle (8 carbon atoms) decreases 
metathesis efficacy. (b) HPLC traces of 30 in the open- (top) and closed conformation (bottom).The 
product peak is highlighted accordingly. (c) Mass spectra of the open- (top) and closed (bottom) 






Supplementary Figure 5. (a) Sequence of the i,i+7 macrocyclized test peptide 9 containing N-
terminal Cys and Met residues. (b) HPLC traces of 9 in the open- (top) and closed conformation 
(bottom).The product peak is highlighted accordingly. (c) Mass spectra of the open- (top) and closed 
(bottom) alkyne crosslink. The HPLC chromatograms are taken from crude reaction mixtures without 





Supplementary Figure 6. (a) Sequence of the i,i+3 macrocyclized test peptide 31 without the N-
terminal Cys and Met residues. After RCAM the alkyne macrocycle is dibrominated using CuBr2. (b) 
HPLC traces of 31 in the open- (top), closed- (middle) and dibrominated conformation (bottom).The 
product peak is highlighted accordingly. (c) Mass spectra of the open- (top) and closed (middle) alkyne 
crosslink and the bibrominated olefin (bottom). The HPLC chromatograms are taken from crude 




Supplementary Figure 7. (a) Sequence of the i,i+4 macrocyclized test peptide 12 without the N-
terminal Cys and Met residues. After RCAM the alkyne macrocycle is dibrominated using CuBr2. (b) 
HPLC traces of 12 in the open- (10, top), closed- (11, middle) and dibrominated conformation (12, 
bottom).The product peak is highlighted accordingly. (c) Mass spectra of the open- (top) and closed 
(middle) alkyne crosslink and the bibrominated olefin (bottom). The HPLC chromatograms are taken 





Supplementary Figure 8. (a) Sequence of the i,i+7 macrocyclized test peptide 32 without the N-
terminal Cys and Met residues. After RCAM the alkyne macrocycle is dibrominated using CuBr2. (b) 
HPLC traces of 32 in the open- (top), closed- (middle) and dibrominated conformation (bottom).The 
product peak is highlighted accordingly. (c) Mass spectra of the open- (top) and closed (middle) alkyne 
crosslink and the dibrominated olefin (bottom). The HPLC chromatograms are taken from crude 





Supplementary Figure 9. (a) Sequence of the i,i+4; i,i+4 bicyclic peptide 16 without the N-terminal 
Cys and Met residues. The olefin and alkyne macrocycle can be closed without affecting the 
orthogonal functionalities. (b) HPLC traces of 16 in the open- (13, top), alkyne-closed- (14, second), 
olefin-closed- (15, third) and fully closed conformation (16, bottom).The product peak is highlighted 





Supplementary Figure 10. Mass spectra of the i,i+4; i,i+4 bicyclic peptide 16. (a) MS pattern of the 
fully open peptide precursor 13. (b) HPLC-MS analysis of the alkyne macrocyclized intermediate (14, 
top). Only the alkyne macrocyclized intermediate and no olefin crosslinked intermediate can be 
detected. MS pattern of the alkyne macrocyclized intermediate (bottom). (c) HPLC-MS analysis of the 
olefin macrocyclized intermediate (15, top). Only the olefin macrocyclized intermediate and no alkyne 
crosslinked intermediate can be detected. MS pattern of the olefin macrocyclized intermediate 
(bottom). (d) MS pattern of the fully closed bicyclic alkyne/olefin peptide 16. (e) MS pattern of the fully 
closed bicyclic olefin/alkyne peptide 16. (f) MS pattern of the fully closed bicyclic one pot synthesis 




Supplementary Figure 11. (a) Sequence of bicyclic peptide 17 without the N-terminal Cys and Met 
residues. The olefin and alkyne macrocycle can be closed without affecting the orthogonal 
functionalities. (b) HPLC traces of 17 in the open- (top), alkyne-closed- (second), olefin-closed- 
(third)
[a] 
and fully closed conformation (17, bottom).The product peak is highlighted accordingly. [a] 
Grubbs 1
st
 gen. catalyst (2 mg/mL), dry toluene, 40°C, 2 x 1.5 h. The HPLC chromatograms are taken 




 Supplementary Figure 12. Mass spectra of bicyclic peptide 17. (a) MS pattern of the fully open 
peptide precursor. (b) HPLC-MS analysis of the alkyne macrocyclized intermediate (top). Only the 
alkyne macrocyclized intermediate and no olefin crosslinked intermediate can be detected. MS pattern 
of the alkyne macrocyclized intermediate (bottom). (c) HPLC-MS analysis of the olefin macrocyclized 
intermediate (top). Only the olefin macrocyclized intermediate and no alkyne crosslinked intermediate 
can be detected. MS pattern of the olefin macrocyclized intermediate (bottom). (d) MS pattern of the 
fully closed bicyclic alkyne/olefin peptide 17. (e) MS pattern of the fully closed bicyclic olefin/alkyne 




Supplementary Figure 13. Fitted FP data for all Rab8 binding peptides. (cmax [Rab8a6-176(GppNHp)] = 
1265 µM); (n = 1) 
 
 
Supplementary Figure 14. Fitted FP data for the best Rab8 binding peptides (triplet measurements). 





Supplementary Figure 15. MST curves for peptide 25. The Results from MST experiments are 
summarized in Supplementary Table 5.  
 
 
Supplementary Figure 16. Fitted initial fluorescence data for peptide 25. (cmax [Rab8a6-176(GppNHp)] 





Supplementary Table 1. Optimization of the metathesis reaction for peptide 8. The resin was dried in 
toluene over molecular sieve (5 Å) for four days while exchanging the solvent daily. The reactions 
were performed in 0.15 mL dry toluene and molecular sieve (5 Å) in a baked out Schlenk tube under 
argon for 3 h at 40° C.  
Resin Conversion [%]
 
Rink Amide Tentagel Quant.
[a] 








Rink Amide Tentagel 12
[b]
 








[a] 1.5 eq. of complex 5 according to resin loading  
[b] 1.5 eq. of complex complex 33 according to resin loading 





Supplementary Table 2. Detailed overview of all synthesized alkyne macrocyclic peptides based on the designed test sequence. 













1 7 i,i+3 8 Fmoc C M W H A 4 D Q 1 F R S H L K 15.52 1064.50584 1064.51051 [m+2H]
2+
 
2 30 i,i+4 8 Fmoc C M W H 1 A D Q 1 F R S H L K 14.94 1064.50584 1064.50663 [m+2H]
2+
 
3 8 i,i+4 9 Fmoc C M W H 2 A D Q 1 F R S H L K 15.54 1071.51366 1071.51565 [m+2H]
2+
 












 i,i+7 11 Fmoc W H 3 A D Q F R S 1 H L K 15.60 1047.42282 1047.42485 [m+2H]
2+
 
8 16 i,i+4; i,i+4 8,9 Fmoc 6 W H A 6 D Q F 2 R S H 1 L K 18.03 720.05102 720.05153 [m+3H]
3+ 




[a] Retention time of crude peptides by analytical HPLC (10-90% MeCN (0.1% TFA), 30 min) 




Supplementary Table 3. Detailed overview of all Rab8a binding peptides. 





















D D E K E Q F L Y H L L S F N  A V 
84 16.58 43 1301.06757 1301.06883 [m+2H]
2+
 






D D E 6 E Q F 6 Y H L L  S F N A V 
>99 20.61 60 1305.56213 1305.56853 [m+2H]
2+
 
2b Ac 98 19.64 65 1059.51256 1059.51703 [m+2H]
2+
 
3 18 F D D E 2 E Q F 2 Y H L L  S F N A V 98 20.04 16 1318.56995 1318.56862 [m+2H]
2+
 
4 19 F D D E 1 E Q F 2 Y H L L  S F N A V 95 19.83 12 1311.56212 1311.56061 [m+2H]
2+
 





 F D D E 2 E Q F 2 Y H L L  S F N A V
 










 F D D E 2 E Q F 1 Y H L L  S F N A V 97 17.52 21 1390.48046 1390.48449 [m+2H]
2+
 






D D E 6 E Q F 6 Y H L 1 S F N 2 V 
98 20.98 13 1344.58560 1344.58642 [m+2H]
2+
 
10b Ac 98 16.70 20 1098.03212 1098.02466 [m+2H]
2+
 
11 26 F D D E 6 E Q F 6 Y H L 2 S F N 1 V 98 20.21 25 1344.58560 1344.58476 [m+2H]
2+
 
12 27 F D D E 2 E Q F 2 Y H L 6  S F N 6 V
 
97 19.88 30 901.39804 901.39818 [m+2H]
3+
 
13 28 F D D E 1 E Q F 2 Y H L 6  S F N 6 V 93 18.62 12 1344.58560 1344.58396 [m+2H]
2+
 




[a] F = Fluorescein-O2OC-,Ac = Acetylated 
[b] Calculated from UV-absorbance at 210 nm 
[c] Retention time of purified peptides by analytical HPLC (10-90% MeCN (0.1% TFA), 30 min) 
[d] Yield was determined according to Fmoc quantification after the 1
st
 amino acid (Val) and quantification of the final peptide by UV absorption at 496 nm 
(fluorescein labeled peptides)  




Supplementary Table 4 Alkyne macrocyclized peptides and their binding affinities towards Rab8a6-




Supplementary Table 5 Results from MST experiments (Supplementary Figure 16, 17). Initial 
fluorescence analysis of peptide 25. Fluorescence data was fitted using the software Monolith Affinity 
Analysis (NanoTemper Technologies). Two individual runs were performed resulting in a Kd of 11 µM 
(average of two measurements).  
Peptide 25 Kd
 
run1 9 ± 8 µM
 





Supplementary Note 1 List of abbreviations. 
AcOH Acetic acid 
Ac2O Acetic anhydride 




DIEA Diisopropylethylamine  
DMF N,N-Dimethylformamide 
EDT 1,2-Ethanedithiol 
EDTA Ethylenediaminetetraacetic acid 
EA Ethylacatate 
ESI Electrospray ionization 
EtOH Ethanol 
FITC Fluorescein isothiocyanate 
Fmoc Fluorenylmethoxycarbonyl 
Fmoc-O2Oc-OH Fmoc-8-amino-3,6-dioxaoctanoic acid 
GppNHp Guanosine-5'-(β, γ-imido)triphosphate 
HCTU O-(6-Chlorobenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate 
HEPES 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid 
HPLC High-performance liquid chromatography 
HRMS High-resolution mass spectrometry 
MeCN Acetonitrile 
MST Microscale thermophoresis 
n.c. No conversion 
NMP N-Methyl-2-pyrrolidone 
NMR Nuclear magnetic resonance 
Oxyma Ethyl (hydroxyimino)cyanoacetate 
PE Petrol ether 
RA Relative Abundance 
RCAM Ring closing alkyne metathesis 
RCM Ring closing metathesis 
SPPS Solid-phase peptide synthesis 
TBABr Tetrabutyl ammonium bromide 
TCEP Tris(2-carboxyethyl)phosphine 







Chemicals and instrumentation 
Unless otherwise noted, chemicals were purchased from Sigma Aldrich, Merck, 
Okeanos, Roth or Alfa Aesar and were used without further purification. Protected 
Fmoc-amino acids and coupling reagents were purchased from Novabiochem and 
Iris Biotech GmbH. Building block 6 for hydrocarbon peptide stapling was purchased 
from Okeanos Tech. Co. LTD. All solvents were purchased from commercial 
suppliers and used without further purification. Analytical HPLC was performed using 
an Agilent 1100 Series with either a C18 HPLC column 3 µm (Macherey Nagel) or a 
C18 HPLC column 1.8 µm (Macherey Nagel). The system was run at a flow rate of 
1.0 mL/min over 30 min using H2O (0.1% TFA) and MeCN (0.1% TFA) as solvents. 
Linear gradients were run over varying periods of time. The efficiency of nucleotide 
exchange was monitored by analytical HPLC using 50 mM KH2PO4 (pH 7.0) and 10 
mM TBABr and MeCN (0.1% TFA) as solvents. HPLC-MS analyses were performed 
with an Agilent 1100 Series connected to a Thermo LCQ Advantage mass 
spectrometer using a C18 HPLC column 3 µm (Macherey Nagel). The system was 
run at a flow rate of 1 mL/min over 15 min using H2O (0.1% formic acid) and MeCN 
(0.1% formic acid) as eluents. Semi preparative HPLC was carried out on a Agilent 
1100 Series using a SP125/10 Nuclear C18 Gravity 5 µm column (Macherey Nagel) 
at a flow rate of 6 mL/min. Linear gradients using H2O (0.1% TFA) and MeCN (0.1% 
TFA) were run over varying periods of time. High resolution mass spectra were 
recorded on a QLT Orbitrap mass spectrometer coupled to an Acceka HPLC-System 
(HPLC column: Hypersyl GOLD, 50 mm x 1mm particle size 1.9 µm, ionization 
method: Electrospray Ionization). Automated Peptide synthesis was performed using 
a CEM-Discover microwave and a CEM-Liberty peptide synthesizer. Fluorescence 
polarization was measured with a Tecan Safire2. Absorbance measurements were 
performed on a Tecan infinite M200 and Thermo scientific Nanodrop 2000c. 1H- and 
13C-NMR spectra were recorded on a Varian Mercury VX 500 or 400 spectrometer at 
room temperature. NMR spectra were calibrated to the solvent signals CDCl3 (7.26 
and 77.16) or DMSO (2.50 and 39.52). MicroScale Thermophoresis (MST) curves 
were measured on a NanoTemper Technologies Monolith NT.115. 
Peptide synthesis 
General 
Peptides were synthesized on solid-phase using the Fmoc-strategy and Rink Amide 
(MBHA) resin, Rink Amide NovaSyn TGR resin or ChemMatrix Rink Amide resin as 
solid support. Solvents and soluble reagents were removed by suction. Washings 
between coupling and deprotection were carried out in DMF and DCM using 1 mL 





Fmoc group deprotection 
The resin was swollen in DMF and treated with a solution of piperidine/DMF (20/80, 
v/v) for 2 x 5 min. Afterwards the resin was washed with DMF (3x), DCM (3x) and 
DMF (3x).  
 
Amino acid coupling 
Fmoc-Xaa-OH (4 eq.) was dissolved in freshly prepared solution of HCTU (3.9 eq., 
0.5 M) with DIEA (8 eq.). Subsequently, this mixture was added to the resin and 
shaken for 30 min at room temperature. For coupling of the Alkyne building blocks 
(1 – 4), the building block 6 and the subsequent amino acid: Fmoc-Xaa-OH (4 eq.) 
was dissolved in DMF in the presence of COMU (3.9 eq.), Oxyma (3.9 eq.) and DIEA 
(8 eq.), added to the resin and shaken for 1 h at  room temperature. Except coupling 
of the Alkyne building blocks 1 – 4 and the alkene building block 6, all couplings were 
performed as double couplings. All equivalents are calculated based on theoretical 
loading of the resin as provided by the vendor.  
 
N-Acetylation 
For preparation of N-acetylated peptides and whenever a quantitative yield even after 
recoupling treatments was not achieved, the free N-terminal amino group was 
acetylated using a solution of Ac2O/DIEA/DMF (1/1/8, v/v/v) for 2 x 10 min at room 
temperature. 
 
Microwave peptide synthesis 
Unmodified peptide sequences were synthesized with a microwave assisted peptide 
synthesizer. Removal of the Fmoc group was performed in piperidine/DMF (20/80, 
v/v), 1 min 30°C (intensity = 40 W) and 5 min 70 °C (intensity = 40 W). Coupling of 
amino acids was performed as double couplings in DMF, Fmoc-Xaa-OH (4 eq., 0.2 
M), HCTU (3.9 eq., 0.5 M) and DIEA (8 eq., 0.2 M in NMP) for 10 min at 80°C 
(intensity = 20 W). Coupling of His- and Cys residues was performed as double 
couplings for 15 min at 60°C (intensity = 20 W). 
 
Fluorescence labelling with FITC 
Prior to fluorescence labelling with FITC a PEG-linker (Fmoc-O2Oc-OH) was coupled 
to the free N-terminus. A mixture of Fmoc-O2Oc-OH (5 eq.), COMU (4.9 eq.), Oxyma 
(4.9 eq.) and DIEA (10 eq.) in DMF was transferred to the resin and shaken at room 
temperature for 2 x 1 h. The resin was drained and washed with DMF (3x). The Fmoc 
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group was removed as described above and the resin was treated with FITC (5 eq.) 
and DIEA (10 eq.) for 16 h at room temperature under exclusion of light. Afterwards, 
the resin was washed with DMF (3x), DCM (3x) and dried to constant weight in 
vacuo. 
 
Ring closing alkyne metathesis 
The dried resin was transferred under argon into a baked out Schlenk tube and 
swollen and shrunken alternating in dry diethyl ether and dry toluene (3x each). 
Afterwards 0.5 mL of a solution of the alkyne metathesis complex 5 (2 mg mL-1) in 
dry toluene was added and the reaction mixture was stirred at 40°C for 1.5 h. During 
the reaction time argon was bubbled through the reaction mixture to evaporate the 2-
butyne. After addition of 0.5 mL of fresh complex 5 solution the mixture was stirred at 
40° C for 1.5 h. The resin was filtered off, washed with toluene (3x), DCM (3x) and 
dried to constant weight. 
 
Ring closing olefin metathesis 
The dried resin was swollen in DCE for 15 min. A solution of Grubbs 1st generation 
catalyst (2 mg mL-1) in DCE was added to the resin and reacted for 2 h at room 
temperature. During the reaction time argon was bubbled through the reaction 
mixture to remove ethene. The procedure was repeated twice and the resin was 
washed with DCE (3x), DCM (3x), DMF (3x).  
 
One pot ring closing alkyne and olefin metathesis 
The dried resin was transferred under argon into a baked out Schlenk tube and 
swollen and shrunk alternating in dry diethyl ether and dry toluene (3x each). 
Afterwards 0.5 mL of a solution of the alkyne metathesis complex 5 (2 mg mL-1) and 
Grubbs 1st generation catalyst (2 mg mL-1) in dry toluene was added and the reaction 
mixture stirred at 40° C for 1.5 h. During the reaction time argon was bubbled through 
the reaction mixture to evaporate the 2-butyne. After addition of 0.5 mL of fresh 
complex solution (alkyne complex 5 and Grubbs 1st generation catalyst) the mixture 
was stirred at 40° C for 1.5 h. The resin was filtered off, washed with toluene (3x), 
DCM (3x) and dried to constant weight. 
 
Dibromination of alkyne macrocycles 
The dried resin was swollen in dry MeCN for 15 min and treated with a mixture of 
CuBr2 in dry MeCN (2 mg mL
-1) for 2 h. The reaction was performed in a Syringe 
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reactor and the procedure was repeated twice. Afterwards, the resin was washed 
with MeCN (3x), DMF (3x), DCM (3x). 
 
Cleavage from the resin 
The dry resin was treated with a solution of TFA/EDT/TIS/H2O (94/1/2.5/2.5, v/v/v/v) 
100 µL 10 mg-1 resin for 2 x 1 h and 1 x 5 min. The solvents were evaporated and the 
crude peptide was precipitated by the addition of cold diethyl ether. After 
centrifugation (10 min, 16.100 x g, 4°C) the supernatant was removed. The crude 
product was dissolved in H2O/MeCN (2/1, v/v) and lyophilized. The crude peptides 
were purified by semi-preparative HPLC. 
 
Fmoc quantification 
A defined amount of dry resin was transferred into an Eppendorf cap and treated with 
0.5 mL deprotection solution for 15 min. The UV absorption of the supernatant was 
determined at 305 nm and the occupation density calculated using Beer-Lambert law 
(ԑ = 7800 cm-1 M-1). 
 
Peptide quantification 
The concentration of fluorescein labeled peptides was determined by UV absorption 
in 20 mM phosphate buffer (pH 8.5) at 496 nm (ԑ = 77.000 cm-1 M-1). The 
concentration of acetylated peptides was determined gravimetrically or via UV 




Protein expression and purification 
Expression and purification of Rab8a6-176 was performed analog to full-length Rab8a 
according to established protocols.1,2  
 
Nucleotide exchange 
Nucleotide exchange was performed according to previously established protocols.2,3 
Briefly, for nucleotide removal Mg2+ was removed by addition of a 5-fold excess of 
EDTA and reacted for 1 h at room temperature. The protein solution was desalted 
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using a PD-10 desalting column Sephadex G-25 DNA Grade (GE Healthcare) with 
elution buffer consisting of 20 mM HEPES (pH 7.5), 50 mM NaCl, 1 mM TCEP. After 
removal of Mg2+ the protein was diluted to 80 - 100 µM before addition of ZnCl2 (500 
µM) and (NH4)2SO4 (200 mM). After addition of alkaline phosphatase (5 U mg
-1 Rab 
protein) the mixture was incubated for 16 h at 4°C. For nucleotide exchange, the 
mixture contained a 5-fold excess of GppNHp during alkaline phosphatase 
incubation. Afterwards, the mixture was desalted using a PD-10 desalting column 
Sephadex G-25 DNA Grade (GE Healthcare) with elution buffer consisting of 25 mM 
HEPES (pH 7.5) 150 mM NaCl, 1 mM TCEP, 1 mM MgCl2 and 1 µM GppNHp.  
 
Fluorescence polarization assay for the determination of dissociation 
constants Kd 
Rab8a6-176 was serially diluted in a buffer containing 25 mM HEPES (pH 7.5), 150 
mM NaCl, 1 mM MgCl2, 1 mM TCEP, 0.01% tween 20 and 1 µM GppNHp (assay 
buffer), treated with 66 nM fluorescein-labeled peptides and incubated for 4 h at room 
temperature. Binding assays were performed in 384-well, small volume, black flat-
bottom, non-binding plates (Greiner). Fluorescence polarization values (λex = 470 nm, 
λem = 525 nm) were determined using a Safire II plate reader (Tecan) at room 
temperature. Initial studies for alkyne macrocyclized peptides were performed as 
single measurements. Final affinity measurements of a subset of peptides were 
performed in triplicates. After correction for changes in fluorescence intensity upon 
binding, the fluorescence anisotoropy data were converted into fraction bound 
(Supplementary equation 1) of the FITC- labeled peptide and fitted to a one-site 
binding model derived from the law of mass action using Kd as the only fitting 
parameter (Supplementary equation 2).4 In case of incomplete binding due to the 
limited solubility of Rab proteins, anisotropy top-values were extrapolated and 
constrained as indicated below. Non-linear regression was performed in Prism 5.0 
(Graphpad).5 
 
               
       
         (        )
 (Supplementary equation 1) 
A: observed anisotropy; Afree: anisotropy of free fluorophore; Abound: anisotoropy of bound fluorophore; 
Q: change in fluorescence intensity between free and bound state 
               
           √(          )
           
    
 (Supplementary equation 2) 
Kd: dissociation constant; LT: total concentration of labeled peptide; cRab: protein concentration 
 
Microscale Thermophoresis (MST) 
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Rab8a6-176 (GppNHp) was serially diluted in assay buffer and treated with 133 nM 
fluorescein-labeled peptide. After incubation for 4 h at room temperature the mixture 
was soaked into capillaries for microscale thermophoresis (MST) measurements. Kd 
values were calculated after initial fluorescene analysis of the obtained MST curves 
using the software Monolith Affinity Analysis (NanoTemper Technologies). 
 
Competition fluorescence polarization assay  
Acetylated peptides were serially diluted in assay buffer (1:1) and were incubated 
with a mixture of 60 nm fluorescein-labeled peptide and Rab8a6-176 (GppNHp) (15 µM 
or 100 µM depending on Kd of the labeled peptide) for 1 h at room temperature. 
Fluorescence polarization was dertermined and half maximal inhibitory 
concentrations (IC50) were calculated by nonlinear regression analysis of dose-





Synthesis of the alkyne building blocks 1-4 was performed according to adapted 
protocols from Y. N. Belokon et al.6 and G. H. Bird et al.7 Schematic representation of 
the synthesis is summarized below. 
 
Synthesis of the alkyne building blocks. (a) PPh3, I2, Imidazol; THF, room temperature, 2 h; (b) KOH, 
24 a-c; DMF, 0°C – room temperature, 2 h; (c) HCl, MeOH, reflux, 1 h; (d) Fmoc-OSu, Na2CO3, 
Dioxane/H2O (1/1, v/v), room temperature, 7d. n = 1, 2, 4 
 
Synthesis of Mo-complexes 5 and 33 
 
Mo-complexes for RCAM 5 and 33 were prepared according to previously 
established procedures.8 
 
Synthesis of alkyne alcohols (34a-c) 
 
Synthesis of alkyne alcohols hex-4-yn-1-ol (34a), hept-5-yn-1-ol (34b) and non-7-yn-





Synthesis of iodo-alkynes (35a-c) 
 
The alcohol 34a-c was converted into the iodo-alkynes 6-iodohex-2-yne (35a), 7-
iodohept-2-yne (35b) and 9-iodonon-2-yne (35c) following established protocols.10 
 
35a 
1H NMR (500 MHz, CDCl3): δ = 3.30 (t, J = 6.8 Hz, 2H), 2.29 – 2.23 (m, 2H), 1.95 (p, 
J = 6.7 Hz, 2H), 1.77 (t, J = 2.6 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ = 77.4, 77.1, 
32.7, 19.9, 5.8, 3.6. 
35b 
1H NMR (500 MHz, CDCl3): δ = 3.20 (t, J = 7.0 Hz, 2H), 2.19 – 2.13 (m, 2H), 1.98 – 
1.88 (m, 2H), 1.77 (t, J = 2.6 Hz, 3H), 1.62 – 1.52 (m, 2H). 13C NMR (126 MHz, 
CDCl3): δ = 78.5, 76.3, 32.7, 29.9, 17.9, 6.5, 3.6. 
35c 
1H NMR (500 MHz, CDCl3): δ = 3.19 (t, J = 7.0 Hz, 2H), 2.16 – 2.08 (m, 2H), 1.87 – 
1.79 (m, 2H), 1.77 (t, J = 2.5 Hz, 3H), 1.51 – 1.44 (m, 2H), 1.43 – 1.36 (m, 4H). 13C 
NMR (126 MHz, CDCl3): δ = 79.2, 75.7, 33.6, 30.2, 28.9, 27.9, 18.8, 7.2, 3.6. 
 
Synthesis of (S, R)-Ala-Ni(II)-BPB (36a,b) 
 
Synthesis of the Ni-complexes 36a and 36b was carried out according to previously 




1H NMR (400 MHz, DMSO) δ = 8.4 (d, J = 7.5 Hz, 2H), 8.0 (d, J = 8.7 Hz, 1H), 7.6 – 
7.5 (m, 4H), 7.4 (t, J = 7.7 Hz, 2H), 7.2 – 7.1 (m, 2H), 7.1 – 7.0 (m, 1H), 6.7 – 6.6 (m, 
1H), 6.5 (dd, J = 8.2, 1.5 Hz, 1H), 4.1 (d, J = 12.3 Hz, 1H), 3.7 – 3.4 (m, 4H), 3.4 – 
3.3 (m, 1H), 2.5 – 2.4 (m, 2H), 2.3 – 2.1 (m, 2H), 1.4 (d, J = 7.0 Hz, 3H). 13C NMR 
(101 MHz, DMSO): δ = 180.9, 179.0, 142.9, 135.5, 134.2, 133.2, 132.1, 131.9, 130.2, 
129.6, 129.5, 129.2, 129.0, 128.3, 128.0, 126.4, 124.0, 120.7, 70.3, 66.6, 63.2, 58.2, 
31.1, 24.4, 22.0. HRMS: calc. [m+H]+ for C28H27N3NiO3 = 512.14787; found = 
512.14789 [m+H]+. HPLC (flow rate 1 mL/min, 10-90% MeCN (0.1% TFA), 13 min) = 
7.93 min. 
36b: 
1H NMR (600 MHz, DMSO) δ = 8.33 (d, J = 8.1 Hz, 2H), 7.93 (d, J = 8.7 Hz, 1H), 
7.60 – 7.52 (m, 2H), 7.48 (m, 2H), 7.35 (dd, J = 10.8, 4.7 Hz, 2H), 7.13 (m, 2H), 7.05 
(m, 1H), 6.64 (m, 1H), 6.49 (dd, J = 8.2, 1.6 Hz, 1H), 4.03 (d, J = 12.4 Hz, 1H), 3.58 – 
3.47 (m, 4H), 3.35 – 3.30 (m, 1H), 2.47 – 2.38 (m, 2H), 2.23 – 2.10 (m, 2H), 1.42 (d, J 
= 7.1 Hz, 3H). 13C NMR (101 MHz, DMSO): δ = 180.2, 178.3, 169.4, 142.2, 134.7, 
133.5, 132.5, 131.4, 131.6, 129.5, 128.9, 128.8, 128.5, 128.3, 127.6, 127.3, 125.7, 
123.3, 120.0, 69.6, 65.9, 62.5, 57.5, 30.4, 23.7, 21.3. HRMS: calc. [m+H]+ for 
C28H27N3NiO3 = 512.14787; found = 512.14810 [m+H]
+. HPLC (flow rate 1 mL/min, 




Synthesis of alkynated (S),(R)-Ala-Ni(II)-BPB (37a-d) 
 
To a solution of 36a,b in 15 mL DMF in a baked out flask under argon, freshly ground 
KOH (5.0 eq.) was added and the reaction mixture stirred for 20 min at 0°C. After 
addition of iodo-alkynes (30a-c) (1.2 eq.) in 2 mL DMF, the mixture was stirred for 20 
min at 0°C and another 2 h at room temperature. The reaction was quenched by 
pouring it onto chilled acetic acid (125 mL, 5%) and extracted with DCM (3 × 80 mL). 
The combined organic layers were washed with water (50 mL), brine and dried over 
MgSO4. After co-evaporation with toluene the pure product was obtained as a red 
solid. Yields: 37a = 98%; 37b = 98%; 37c = 99%; 37d = 95%. 
37a: 
1H NMR (500 MHz, DMSO) δ = 8.33 (d, J = 7.1 Hz, 2H), 7.92 – 7.86 (m, 1H), 7.54 – 
7.47 (m, 3H), 7.46 – 7.38 (m, 3H), 7.24 (t, J = 7.5 Hz, 1H), 7.15 (d, J = 7.6 Hz, 1H), 
7.11 – 7.04 (m, 1H), 6.68 – 6.61 (m, 1H), 6.57 (dd, J = 8.4, 1.5 Hz, 1H), 4.10 – 4.06 
(m, 1H), 3.68 (d, J = 12.4 Hz, 1H), 3.52 (t, J = 8.3 Hz, 1H), 3.42 – 3.35 (m, 1H), 3.09 
– 2.98 (m, 1H), 2.64 – 2.54 (m, 1H), 2.48 – 2.41 (m, 2H), 2.26 – 2.19 (m, 2H), 2.18 – 
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2.06 (m, 2H), 2.05 – 1.95 (m, 1H), 1.79 – 1.74 (m, 3H), 1.75 – 1.68 (m, 1H), 1.64 – 
1.52 (m, 1H), 0.99 (s, J = 5.1 Hz, 3H). 13C NMR (126 MHz, DMSO) δ = 180.1, 180.0, 
171.6, 141.8, 136.2, 134.7, 132.9, 131.5, 130.8, 130.6, 129.3, 128.5, 128.4, 127.8, 
127.7, 127.2, 126.9, 123.4, 119.9, 78.8, 76.6, 76.3, 69.6, 63.0, 57.0, 39.9, 30.1, 28.7, 
25.1, 22.7, 18.1, 3.1. HRMS: calc. [m+H]+ for C34H36N3NiO3 = 592.21047; found = 
592.21180 [m+H]+. HPLC (flow rate 1 mL/min, 10-90% MeCN (0.1% TFA), 13 min) = 
9.43 min. 
37b: 
1H NMR (500 MHz, DMSO) δ = 8.32 (d, J = 7.1 Hz, 2H), 7.92 – 7.83 (m, 1H), 7.55 – 
7.50 (m, 3H), 7.47 – 7.39 (m, 3H), 7.25 (t, J = 7.4 Hz, 1H), 7.13 (d, J = 8.3 Hz, 1H), 
7.09 – 7.04 (m, 1H), 6.67 – 6.54 (m, 2H), 4.06 (d, J = 12.4 Hz, 1H), 3.70 (d, J = 12.4 
Hz, 1H), 3.54 – 3.45 (m, 1H), 3.37 (dd, J = 18.7, 9.7 Hz, 1H), 3.12 – 2.99 (m, 1H), 
2.55 – 2.50 (m, 2H), 2.48 – 2.41 (m, 1H), 2.26 – 2.20 (m, 2H), 2.17 – 2.06 (m, 2H), 
1.99 – 1.92 (m, 1H), 1.65 – 1.58 (m, 3H), 1.50 – 1.37 (m, 4H), 1.06 (s, J = 8.9 Hz, 
3H). 13C NMR (126 MHz, DMSO) δ = 180.5, 179.9, 171.7, 141.7, 136.3, 134.7, 132.7, 
131.5, 131.3, 130.7, 130.4, 129.3, 128.5, 128.4, 127.9, 127.8, 127.1, 126.9, 123.5, 
119.9, 79.1, 76.7, 76.1, 69.7, 62.9, 56.9, 40.0, 30.2, 29.0, 28.4, 24.4, 22.7, 18.1, 2.9. 
HRMS: calc. [m+H]+ for C35H38N3NiO3 = 606.22613; found = 606.22693 [m+H]
+. 
HPLC (flow rate 1 mL/min, 10-90% MeCN (0.1% TFA), 13 min) = 9.61 min. 
 
37c: 
1H NMR (500 MHz, DMSO) δ = 8.32 (d, J = 7.4 Hz, 2H), 7.86 (d, J = 8.6 Hz, 1H), 
7.51 (s, 3H), 7.42 (t, J = 7.6 Hz, 3H), 7.25 (t, J = 7.4 Hz, 1H), 7.14 – 7.05 (m, 2H), 
6.64 (t, J = 7.6 Hz, 1H), 6.57 (d, J = 8.4 Hz, 1H), 4.07 (d, J = 12.4 Hz, 1H), 3.69 (d, J 
= 12.4 Hz, 1H), 3.51 (dd, J = 9.7, 6.8 Hz, 1H), 3.40 – 3.34 (m, 1H), 3.04 (dd, J = 19.0, 
9.0 Hz, 1H), 2.48 – 2.42 (m, 2H), 2.40 – 2.32 (m, 1H), 2.18 – 2.08 (m, 4H), 1.88 – 
1.76 (m, 1H), 1.72 (s, 3H), 1.45 (m, 4H), 1.43 – 1.19 (m, 4H), 1.05 (s, 3H). 13C NMR 
(126 MHz, DMSO) δ = 180.6, 180.0, 171.6, 141.7, 136.3, 134.7, 132.8, 131.5, 130.7, 
130.5, 129.3, 128.5, 128.5, 127.9, 127.8, 127.1, 126.9, 123.6, 120.0, 79.3, 76.8, 
75.7, 69.6, 62.9, 57.0, 39.8, 30.2, 29.0, 28.6, 28.4, 28.3, 25.3, 22.8, 18.0, 3.1. HRMS: 
calc. [m+H]+ for C37H42N3NiO3 = 634.25742; found = 634.25868 [m+H]
+. HPLC (flow 
rate 1 mL/min, 10-90% MeCN (0.1% TFA), 11 min) = 6.96 min. 
 
37d: 
1H NMR (500 MHz, DMSO) δ = 8.33 (d, J = 7.1 Hz, 2H), 7.90 – 7.86 (m, 1H), 7.56 – 
7.48 (m, 3H), 7.46 – 7.39 (m, 3H), 7.24 (t, J = 7.5 Hz, 1H), 7.15 (d, J = 7.7 Hz, 1H), 
7.11 – 7.06 (m, 1H), 6.67 – 6.61 (m, 1H), 6.61 – 6.55 (m, 1H), 4.07 (d, J = 12.4 Hz, 
1H), 3.68 (d, J = 12.4 Hz, 1H), 3.57 – 3.49 (m, 1H), 3.41 – 3.33 (m, 1H), 3.10 – 2.97 
(m, 1H), 2.67 – 2.53 (m, 1H), 2.49 – 2.40 (m, 2H), 2.21 (s, J = 2.1 Hz, 2H), 2.18 – 
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2.05 (m, 2H), 2.02 – 1.95 (m, 1H), 1.76 (t, J = 2.4 Hz, 3H), 1.74 – 1.68 (m, 1H), 1.63 
– 1.52 (m, 1H), 0.99 (s, 3H). 13C NMR (126 MHz, DMSO) δ = 180.1, 180.0, 171.6, 
141.8, 136.2, 134.7, 132.9, 131.5, 130.8, 130.6, 129.3, 128.5, 128.4, 127.8, 127.7, 
127.2, 126.9, 123.4, 119.9, 78.8, 76.6, 76.3, 69.6, 63.0, 57.0, 39.9, 30.1, 28.7, 25.1, 
22.7, 18.1, 3.1. HRMS: calc. [m+H]+ for C34H36N3NiO3 = 592.21047; found = 
592.21180 [m+H]+. HPLC (flow rate 1 mL/min, 10-90% MeCN (0.1% TFA), 13 min) = 
9.16 min. 
 
Synthesis of unprotected -methyl--alkinyl amino acids (38a-d) 
 
To a solution of 37a-d in MeOH (40 mL), conc. hydrochloric acid (10 eq.) was added 
and the reaction mixture refluxed at 80 °C for 1 h. The reaction mixture was allowed 
to cool to room temperature and concentrated in vacuo. After addition of 20 mL water 
(20 mL) the aqueous layer was extracted with DCM (3 × 20 mL). The combined 
organic layers were washed with brine, dried over MgSO4 and concentrated under 
reduced pressure. Recovered BPB was purified by precipitation as hydrochloric salt 
from acetone solution.12 The aqueous layer was dried by lyophilization and the crude 




Synthesis of Fmoc-protected -methyl--alkinyl amino acids (1-4) 
 
To a solution of the crude unprotected -methyl--alkynyl amino acid in H2O/dioxane 
(40 mL, 1/1, v/v), Na2CO3 (4 eq.) and Fmoc-OSu (1.2 eq.) were added and stirred at 
room temperature for 7 d. The reaction was monitored using HPLC-MS analysis, 
daily and subsequently fresh Fmoc-Osu (0.5 eq.) was added. After addition of water 
(100 mL) the pH of the aqueous layer was set to 2-4 using aqueous hydrochloric acid 
and the aqueous layer was extracted with ethylacatate (3 x 100 mL). The combined 
organic layers were washed with brine, dried over MgSO4 and concentrated under 
reduced pressure. The crude product was purified via column chromatography (Rf = 
0.45, PE:EA 1:1; 0.1% AcOH) and obtained as a pale yellow solid. Yields: 1a = 98%; 
2b = 97%; 3c = 86%; 4d = 90%. 
Fmoc-1-OH 
1H NMR (500 MHz, DMSO) δ = 12.38 (s,1H), 7.89 (d, J = 7.5 Hz, 2H), 7.71 (d, J = 
7.4 Hz, 2H), 7.43 (s, 1H), 7.41 (d, J = 7.3 Hz, 2H), 7.33 (t, J = 7.4 Hz, 2H), 4.31 – 
4.22 (m, 2H), 4.22 – 4.16 (m, 1H), 2.14 – 2.01 (m, 2H), 1.88 – 1.79 (m, 1H), 1.79 – 
1.73 (m, 1H), 1.72 (s, 3H), 1.45 – 1.33 (m, 2H), 1.32 (s, 3H). 13C NMR (126 MHz, 
DMSO) δ = 175.2, 154.6, 143.8, 140.7, 127.6, 127.0, 125.2, 120.0, 79.1, 75.8, 65.2, 
58.1, 46.7, 36.0, 23.3, 22.5, 18.3, 3.1. HRMS: calc. [m+H]+ for C24H26NO4 = 
392.18563 ; found = 392.18459 [m+H]+, 414.16581 [m+Na]+. HPLC: (flow rate 1 




1H NMR (500 MHz, DMSO) δ = 12.37 (s, 1H), 7.89 (d, J = 7.5 Hz, 2H), 7.72 (d, J = 
7.4 Hz, 2H), 7.42 (d, J = 7.4 Hz, 2H), 7.36 (d, J = 16.1 Hz, 1H), 7.33 (t, J = 7.4 Hz, 
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2H), 4.34 – 4.22 (m, 2H), 4.22 – 4.18 (m, 1H), 2.17 – 2.03 (m, 2H), 1.76 (s, 1H), 1.69 
(t, J = 2.4 Hz, 3H), 1.68 – 1.59 (m, 1H), 1.45 – 1.35 (m, 2H), 1.33 (s, 3H), 1.30 – 1.19 
(m, 2H). 13C NMR (126 MHz, DMSO) δ = 175.3, 154.7, 143.8, 140.7, 127.6, 127.0, 
125.2, 120.0, 79.1, 75.7, 65.2, 58.2, 46.7, 36.2, 28.7, 22.6, 22.4, 18.0, 3.1. HRMS: 
calc. [m+H]+ for C25H28NO4 = 406.20128 ; found = 406.20119 [m+H]
+, 428.18273 




1H NMR (500 MHz, DMSO) δ = 12.32 (s, 1H), 7.89 (d, J = 7.5 Hz, 2H), 7.72 (d, J = 
7.4 Hz, 2H), 7.41 (t, J = 7.4 Hz, 2H), 7.37 (s, 1H), 7.35 – 7.30 (m, 2H), 4.32 – 4.22 
(m, 2H), 4.22 – 4.17 (m, 1H), 2.11 – 2.03 (m, 2H), 1.75 (s, 1H), 1.71 (t, J = 2.4 Hz, 
3H), 1.69 – 1.61 (m, 1H), 1.43 – 1.35 (m, 2H), 1.33 (s, 3H), 1.25 (s, 2H), 1.23 (m, 
4H). 13C NMR (126 MHz, DMSO) δ = 175.4, 154.7, 143.8, 140.7, 127.6, 127.0, 125.2, 
120.0, 79.3, 75.6, 65.2, 58.3, 46.7, 36.6, 28.7, 28.4, 28.1, 23.1, 22.3, 18.0, 3.1. 
HRMS: calc. [m+H]+ for C27H31NO4 = 434.23258 ; found = 434.23458 [m+H]
+, 
456.21638 [m+Na]+. HPLC: (flow rate 1 mL/min, 10-90% MeCN (0.1% TFA), 11 min) 
= 7.18 min. 
 
Fmoc-4-OH 
1H NMR (500 MHz, DMSO) δ = 12.37 (s, 1H), 7.89 (d, J = 7.5 Hz, 2H), 7.72 (d, J = 
7.4 Hz, 2H), 7.43 (s, 1H), 7.42 (t, J = 7.6 Hz, 2H), 7.33 (t, J = 7.4 Hz, 2H), 4.29 – 4.22 
(m, 2H), 4.22 – 4.17 (m, 1H), 2.14 – 2.01 (m, 2H), 1.89 – 1.79 (m, 1H), 1.76 (s, J = 
11.9 Hz, 1H), 1.72 (s, 3H), 1.43 – 1.34 (m, 2H), 1.32 (s, 3H). 13C NMR (126 MHz, 
DMSO) δ = 175.2, 154.7, 143.8, 140.7, 127.6, 127.0, 125.3, 120.0, 79.0, 75.9, 65.2, 
58.1, 46.7, 36.0, 23.2, 22.4, 18.3, 3.1. HRMS: calc. [m+H]+ for C24H26NO4 = 
392.18563 ; found = 392.18504 [m+H]+, 414.16645 [m+Na]+. HPLC: (flow rate 1 
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